Trial · NCT00360412
Adverse events214
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 214
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fall | Injury, poisoning and procedural complications | Perampanel (Placebo During Core Study) | 24 | 333 | |
| other | Fall | Injury, poisoning and procedural complications | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 32 | 664 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Perampanel (Placebo During Core Study) | 14 | 333 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 35 | 664 | |
| other | Dyskinesia | Nervous system disorders | Perampanel (Placebo During Core Study) | 33 | 333 | |
| other | Dyskinesia | Nervous system disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 72 | 664 | |
| other | On and off phenomenon | Nervous system disorders | Perampanel (Placebo During Core Study) | 42 | 333 | |
| other | On and off phenomenon | Nervous system disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 73 | 664 | |
| other | Somnolence | Nervous system disorders | Perampanel (Placebo During Core Study) | 22 | 333 | |
| other | Somnolence | Nervous system disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 33 | 664 | |
| other | Insomnia | Psychiatric disorders | Perampanel (Placebo During Core Study) | 17 | 333 | |
| other | Insomnia | Psychiatric disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 37 | 664 | |
| serious | Parkinson's disease | Nervous system disorders | Perampanel (Placebo During Core Study) | 1 | 333 | |
| serious | Parkinson's disease | Nervous system disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 4 | 664 | |
| serious | On and off phenomenon | Nervous system disorders | Perampanel (Placebo During Core Study) | 1 | 333 | |
| serious | On and off phenomenon | Nervous system disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 2 | 664 | |
| serious | Akinesia | Nervous system disorders | Perampanel (Placebo During Core Study) | 1 | 333 | |
| serious | Akinesia | Nervous system disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 1 | 664 | |
| serious | Dyskinesia | Nervous system disorders | Perampanel (Placebo During Core Study) | 2 | 333 | |
| serious | Dyskinesia | Nervous system disorders | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | 0 | 664 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00360412/events